This announcement is a separate document:
Chimeric Therapeutics Ltd: University of Pennsylvania joins CHM CDH17 Phase 1/2 trial
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.